Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;7(4):92-5.

Treatment guidelines and prognosis of immune reconstitution inflammatory syndrome patients: a review

Anup R Murthy  1 , Rekha Marulappa  2 , Usha Hegde  3 , Damodhar Kappadi  4 , U K Ambikathanaya  5 , Priyanka Nair  2
Affiliations
Review

Treatment guidelines and prognosis of immune reconstitution inflammatory syndrome patients: a review

Anup R Murthy et al. J Int Oral Health. 2015 Apr.

Abstract

Immune reconstitution inflammatory syndrome (IRIS) is an "unmasking" or paradoxical worsening of a pre-existing infection after commencement of highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV) - infected patients. The use of HAART in the management of HIV patients restores immune responses against pathogens however in few patients, the reconstituted immune system leads to IRIS. As the treatment protocols are not standardized for IRIS, this leads to short-term morbidity or in some cases also mortality. Therefore, treatment in these patients is a huge challenge and further more research regarding the immunopathogenesis, diagnosis and management of IRIS should be well thought-out. To understand the immunopathogenesis of IRIS it will be difficult to elucidate the intrinsic dynamics of immune cells after initiation of HAART but, there are few biomarkers which help to predict or diagnose IRIS and develop specific treatment, following initiation of HIV therapy. This review is an attempt to put light on those patients with IRIS with treatment guidelines for the management of the progression of it.

Keywords: CD4 cell count; highly active antiretroviral therapy; human immunodeficiency virus; immune reconstitution inflammatory syndrome; management.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None

References

    1. Gaitan Cepeda LA, Ceballos Salobreña A, López Ortega K, Arzate Mora N, Jiménez Soriano Y. Oral lesions and immune reconstitution syndrome in HIV+/AIDS patients receiving highly active antiretroviral therapy. Epidemiological evidence. Med Oral Patol Oral Cir Bucal. 2008;13(2):E85–93. - PubMed
    1. Surendra K, Soneja S, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS) Indian J Med Res. 2011;134:866–77. - PMC - PubMed
    1. Tsang CS, Samaranayake LP. Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review. Oral Dis. 2010;16(3):248–56. - PubMed
    1. Dagnachew M, et al. Immunopathogenesis, treatment and prevention of immune reconstitution inflammatory syndrome (IRIS) Int J Med Med Sci. 2012;2(11):211–7.
    1. Ortega KL, Ceballos-Salobreña A, Gaitán-Cepeda LA, Magalhães MG. Oral manifestations after immune reconstitution in HIV patients on HAART. Int J STD AIDS. 2008;19(5):305–8. - PubMed

LinkOut - more resources